Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis

Abstract

Objectives: Issue recommendations on practical aspects of the monitoring of levels of biological drugs that may be useful for rheumatologists.

Methods: We conducted a systematic review of studies in which drug and anti-drug antibody levels were determined in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) to study whether they could predict different outcomes. In light of the results of the review, a group of experts discussed under what circumstances testing biological drug levels and their antibodies could be useful. The discussion resulted in a series of clinical questions that were answered with the scientific evidence collected, and in algorithms that facilitate decision making.

Results: It was established that the determination of drug levels can be especially useful in two clinical situations, on treatment failure (primary or secondary) and on sustained remission. It is also reviewed which laboratory technique and timing for sample drawing are the most suitable for the measurement. Recommendations are issued on the interpretation of drug levels and on factors to be taken into account (for example, body mass index and disease modifying drugs).

Conclusions: Evidence-based algorithms and guidelines have been established to test drug levels and anti-drug antibodies in patients with RA and SpA, which can help clinical decision making.

Keywords: Anti-TNF; Anti-drug antibody levels; Artritis reumatoide; Biologics; Biológicos; Drug levels; Espondiloartritis; Niveles de anticuerpos anti-fármaco; Niveles de fármaco; Rheumatoid arthritis; Spondyloarthritis; TNF-inhibitors; Tocilizumab.